+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Healthcare Licensing Trends: Japan-Neurology

  • ID: 4861801
  • Report
  • September 2019
  • Region: Global
  • 56 pages
  • FinGlobe, Inc
1 of 4

FEATURED COMPANIES

  • Aikomi, Ltd.
  • Biogen Japan Ltd.
  • Fukuda Denshi Co Ltd.
  • iPS Academia Japan, Inc.
  • Medrx Co Ltd
  • Osaka University
  • MORE
This trends report provides comprehensive analysis on all licensing deals and negotiations reported for the healthcare companies of Japan in the Neurology medicine group during January 1, 2018 to August 31, 2019, categorized and summarized by various important aspects such as healthcare sub-sectors, market capitalization groups, across key regions, licensing payment arrangements, and worldwide vs domestic licensing. Such detailed analysis helps to understand the licensing trends and directions during this time period in the healthcare segments of Japan for the Neurology medicine group.

Analytical data coverage:
  • January 1, 2018 to August 31, 2019 licensing deals and negotiations
  • 50+ healthcare licensing news for Japanese companies (40) in the Neurology medicine group
  • Small-mid-large cap companies covered - LargeCap (43%)
  • Listed and non-listed companies included
  • 4 healthcare sub-sectors covered - Pharmaceuticals (43%), Biotech (22.5%), Medical Devices (12%), Healthcare Services (22.5%)
  • 8+ variables analyzed
Key Features:
  • 20 months’ healthcare licensing transactions of Japan in the Neurology medicine group analyzed at one place
  • Small, medium and big multinational/non-multinational companies covered
  • Curated categorizations of licensing details
  • Licensing trends and directions summarized
The Report is useful to:
  • Healthcare companies of Japan planning to introduce products in other countries in the Neurology medicine group
  • Companies active in R&D and seeking new market base
  • Healthcare company executives of Japan negotiating licensing deals in the Neurology medicine group
  • Investors analyzing varied kinds of transaction options for licensing deals in Japan in the Neurology medicine group
Key analysis provided: January 2018-August 2019
  • Total number of licensing deals signed by companies of Japan in the Neurology medicine group
  • Total number of companies/institutes of Japan involved in the licensing deals in the Neurology medicine group
  • Most licensing deals signed by companies of which sub-industry within healthcare sector in the Neurology medicine group
  • Most licensing deals signed by which market capitalization group’s companies in the Neurology medicine group
  • Licensing payment arrangements most followed in the licensing deals in the Neurology medicine group
  • Number of domestic and worldwide licensing in the Neurology medicine group
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aikomi, Ltd.
  • Biogen Japan Ltd.
  • Fukuda Denshi Co Ltd.
  • iPS Academia Japan, Inc.
  • Medrx Co Ltd
  • Osaka University
  • MORE
Introduction
Research Design

Chapter 1: Analysis of healthcare inventions of Japan in the Neurology medicine group licensed during last twenty months
1.1 Healthcare sub-sectors with most licensing deals
1.2 Market capitalization groups with most licensing deals
1.3 Licensing payment arrangements most followed
1.4 Worldwide licensing vs domestic licensing

Chapter 2: Analysis of licensing deals of Japan in the Neurology medicine group by key attributes during last twenty months
2.1 For each of the healthcare sub-sectors
2.2 For each of the marketcap groups
2.3 Across each of the regions

Chapter 3: Summary and conclusions

Appendices
Appendix 1 Healthcare inventions licensed for Japan in the Neurology medicine group during last twenty months - By company name
Appendix 2 List of companies/institutes covered - By company name
Appendix 3 List of companies/institutes covered - By sub-industry and company name
Appendix 4 List of companies/institutes covered - By market capitalization group and company name
Appendix 5 List of non-listed companies covered - By country and company name
Appendix 6 List of not-for-profit groups covered - By country and institute name
Appendix 7 List of companies/institutes covered - By terms of payment and company name
Appendix 8 Licensing deals discontinued for Japan in the Neurology medicine group during last twenty months
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Aikomi, Ltd.
  • Allm Inc.
  • Astellas Pharma Inc.
  • Biogen Japan Ltd.
  • Eisai Co. Ltd.
  • Fujirebio Inc.
  • Fukuda Denshi Co Ltd.
  • Gene Therapy Research Institution Co Ltd
  • GeneDesign, Inc
  • Healios K.K.
  • Hisamitsu Pharmaceutical Co Inc
  • iPS Academia Japan, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Keio University School of Medicine
  • KinoPharma Inc.
  • Kobe City Hospital Organisation
  • Kyowa Hakko Kirin Co. Ltd.
  • Medipal Holdings Corp.
  • Medrx Co Ltd
  • Mitsubishi Tanabe Pharma Corporation
  • National Cancer Center Hospital East (The)
  • National Institute of Biomedical Innovation, Health and Nutrition (The)
  • National Institutes for Quantum and Radiological Science and Technology
  • Niigata University
  • Nippon Shinyaku, Co., Ltd.
  • Nipro Corporation
  • Ono Pharmaceutical Co., Ltd.
  • Osaka University
  • Otsuka Pharmaceutical Co., Ltd.
  • PeptiDream Inc.
  • ReproCELL
  • Shionogi & Co. Ltd.
  • Sosei Group Corporation
  • Sumitomo Dainippon Pharma Co Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teijin Limited
  • TMS Co., Ltd
  • Tokyo Metropolitan Institute of Gerontology
  • Tokyo Women’s Medical University
  • UCB Japan Co., Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll